- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04760353
The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome
January 4, 2024 updated by: Goran Hauser, University Hospital Rijeka
The Effect of a Probiotic Mixture on the Symptoms and Fecal Microbiota in Obese Patients With Irritable Bowel Syndrome, Randomised, Double-blind, Controlled Study
The objective of the current study is to evaluate the effect of a probiotic mixture on the adequate relief and faecal microbiota in obese patients with irritable bowel syndrome
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
- The treatment period will last 8 weeks and after the treatment period, patients will be followed-up for another 2 weeks. Thus the overall trial period is the 10-week study period and end of 10th week is the end of the trial.
- Planned visits to gastroenterologists are at the screening period (-1 week), randomization period (0 weeks), and at the end of the treatment period (8th week).
- Patients will be instructed that unplanned visits to gastroenterologist are allowed only in case of a need or an urgency [e.g., adverse reactions, clinical deterioration and/or need for additional irritable bowel syndrome (IBS) management]. Unplanned visits will be recorded and does not exclude patients from the trial.
- For assessing other needed parameters (e.g., adequate relief, adverse reactions, irritable bowel syndrome (IBS) management) patients will be assessed by a physician, using an interactive voice response by telephone.
- Laboratory tests will be performed by certified clinical laboratories. Blood samples will be obtained by experienced trial nurses at the time of randomization (0 weeks).
- Anthropometric measurements will be assessed at the baseline and at the end of the treatment period (8th week).
- Irritable bowel syndrome (IBS) management (non-medication and medication therapy) will be assessed at the baseline, during the trial at the planned and unplanned visits to gastroenterologists, and at the end of the trial (by a physician using an interactive voice response by telephone). In a case of clinical deterioration IBS management is allowed during the trial and each will be recorded by gastroenterologists.
- Participants will receive 112 powder portion bags at the beginning of the trial and will be instructed to return the container after the 8-week treatment period. Leftover powder portion bags will be counted at the end of the treatment period (8th week) to estimate compliance. Compliant is considered a participant where no leftover powder portion bags will be recorded. Otherwise, the participant is considered non-compliant.
- Safety will be ensured by following adverse reactions during the trial. Scheduled assessment of adverse reactions is at the time of randomization, after 4 weeks, 8 weeks, and at the end of the trial. Responses will be recorded by a physician, at the planned visit of gastroenterologists and/or using an interactive voice response by telephone. Unscheduled recording of adverse reactions is during the entire trial by patients which will be instructed at the randomization period to report any adverse reactions to gastroenterologists using an interactive voice response by telephone. In a case of severe adverse reactions patients will be withdrawn from the trial and if needed. In case of a need or urgency (e.g., adverse reactions, clinical deterioration) clinical management will be provided in line with the best medical practice, by gastroenterologists and/or medical specialists depending on a medical condition.
- Patients can withdrawal from the trial any time. During the trial period withdrawal and its reason will be assessed by gastroenterologists at the visits or using an interactive voice response by telephone. Patients will be instructed in a case of a withdrawal to inform gastroenterologists and report the reason. In a lack of response the reason will be considered as other.
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: GORAN HAUSER, MD, PhD
- Phone Number: 0981820726
- Email: goran.hauser@uniri.hr
Study Contact Backup
- Name: Eugen Javor, MPharm
- Email: eugen.javor@gmail.com
Study Locations
-
-
-
Rijeka, Croatia, 51000
- Recruiting
- University Hospital Rijeka
-
Contact:
- Goran Hauser, MD, PhD
- Phone Number: 385 51 658 122
- Email: goran.hauser@medri.uniri.hr
-
Principal Investigator:
- Goran Hauser, MD, PhD
-
-
Kresimirova 42
-
Rijeka, Kresimirova 42, Croatia, 51000
- Recruiting
- Clinical Hospital Centre
-
Contact:
- Goran Hauser, MD, PhD
- Phone Number: 385 98 18 20 726
- Email: goran.hauser@medri.uniri.hr
-
Contact:
- Patricia Mikic, ass
- Phone Number: 385 51 658 122
- Email: interna-rijeka@kbc-rijeka.hr
-
Principal Investigator:
- Goran Hauser, MD,PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Obese [Body mass index (BMI) ≥30] men or women with confirmed IBS (all subtypes based on Rome IV Diagnostic Criteria for IBS) aged between 18 and 65 years.
- Written informed consent.
Exclusion Criteria:
- Pregnancy or lactation
- Severe systemic illness [cancer, gastrointestinal illness (e.g., colitis, Crohn's disease, celiac disease, recurrent diverticulitis), chronic renal failure, an endocrine disorder, metabolic disorder, angina, congestive heart failure, uncontrolled hypertension] or severely impaired general health
- Organic abnormality which is excluded by full blood count, C-reactive protein or erythrocyte sedimentation rate, and thyroid-stimulating hormone for constipated IBS participants. To exclude other organic lower gastrointestinal disease faecal calprotectin will be checked, and celiac test and colonoscopy will be performed if needed.
- Previous abdominal surgery except for appendectomy, cholecystectomy and abdominal wall hernia repair
- History of psychiatric disorder
- History of participation in another clinical trial within 3 months before the onset of this trial
- Medications that could affect the outcomes: oral steroid, sulfasalazine, cholestyramine, misoprostol and probiotics usage 3 months prior to and during the study; and antacids with magnesium or aluminium usage during the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Probiotic
one powder portion bag of the probiotic mixture (OMNi-BiOTiC STRESS) containing 9 human bacterial strains [Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51 Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)] and vitamin B (B2, B6, B12), self-administered orally twice a day for 8 weeks
|
OMNi-BiOTiC STRESS containing 9 human bacterial strains [Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)] and vitamin B (B2, B6, B12),
|
Placebo Comparator: Placebo
one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.
|
one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adequate relief
Time Frame: eight weeks
|
Adequate relief (AR) related question of overall IBS symptoms "In the past 7 days have you had adequate relief of your IBS pain and discomfort?" which will be assessed weekly for 10 weeks (starting with 0 week till 10th week).
A responder is defined as a patient who experiences AR (answers YES to AR related question) for at least 50% of the 10-week study period (5 of the 10 weekly assessments).
10-point analog scale will be used for the measurement of response rate among patients in each group.
|
eight weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The fecal flora compositions
Time Frame: eight weeks
|
The fecal flora compositions will be analyzed by Real Time polymerase chain reaction (PCR) for specific strain detection.
The concordance rate of each patient's denaturing gradient gel electrophoresis (DGGE) profile before and after the treatment will be measured by the visual scale where each band of the DGGE profile represents a different organism and the similarity of band locations represents the same composition of the population of organisms.
|
eight weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IBS Severity
Time Frame: eight weeks
|
IBS severity will be assessed by the IBS symptom severity score (IBS SSS) questionnaire administered at the trial site by gastroenterologists and filled by patients at the time of randomization (0 weeks) and at the end of treatment (8th week).
IBS-SSS consists of five items [abdominal pain, number of days with abdominal pain, bloating/distension, satisfaction with bowel habits, and IBS-related quality of life (QOL)], and each measure is rated from 0 to 100, with total scores ranging from 0 to 500.
Participants with scores of <175, 175-300, and >300 are classified as mild, moderate, and severe groups.
|
eight weeks
|
IBS QOL
Time Frame: eight weeks
|
IBS health related quality of life (QoL) will be assessed by IBS-36 questionnaire administered at the trial site by gastroenterologists and filled by patients at the time of randomization (0 week) and at the end of treatment (8th week).
The IBS-36 consists of 36 questions scored on a 7-point Likert scale ranging from 0 through to 6, giving a maximal total score of 216.
A final score is a sum of the scores of the 36 questions, with question 18 being reverse scored (i.e., for a patient score of 0, a score of 6 is entered).
This instrument is negatively scored (i.e., a lower score equates to a better QoL) and assesses patients' symptoms over a last 2 months.
|
eight weeks
|
Psychological distress
Time Frame: eight weeks
|
Psychological distress will be assessed by Hospital Anxiety and Depression Scale (HADS) questionnaire administered at the trial site by gastroenterologists and filled by patients at the time of randomization (0 week) and at the end of treatment (8th week).
HADS is a 14-item scale with seven items each for anxiety and depression subscales.
Scoring for each item ranges from zero to three.
A subscale score >8 denotes anxiety or depression.
|
eight weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: GORAN HAUSER, MD, PhD, KBC Rijeka; Medicinski fakultet Sveučilišta u Rijeci
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 10, 2021
Primary Completion (Estimated)
August 10, 2024
Study Completion (Estimated)
October 10, 2024
Study Registration Dates
First Submitted
January 26, 2021
First Submitted That Met QC Criteria
February 14, 2021
First Posted (Actual)
February 18, 2021
Study Record Updates
Last Update Posted (Estimated)
January 8, 2024
Last Update Submitted That Met QC Criteria
January 4, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Omni Stress 1.1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
We will share all necessary documents which are not under GDPR protection
IPD Sharing Time Frame
after enrollment, 50% of patients and will be available 6 months after study termination
IPD Sharing Access Criteria
Patients, Ethic committee members, regulatory organisations
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Probiotic mixture (OMNi-BiOTiC STRESS)
-
Medical University of GrazActive, not recruiting
-
Medical University of GrazCBmed Ges.m.b.H.Active, not recruiting
-
Medical University of GrazCompletedPatients on Long-term Proton Pump Inhibitor TherapyAustria
-
Kinderwunsch Institut GmbHInstitut AllergoSanCompleted
-
Massachusetts General HospitalWinclove Bio Industries BVActive, not recruitingInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisUnited States
-
Bionou Research, S.L.RecruitingRosacea | Rosacea, Papulopustular | Rosacea Papular TypeSpain
-
Policlinico HospitalUnknown
-
University of HelsinkiUnknownFood Hypersensitivity | Asthma | Atopic Dermatitis | Allergic Conjunctivitis | Allergic Rhinitis, SeasonalFinland
-
Hepatopancreatobiliary Surgery Institute of Gansu...CompletedHeart Valve DiseasesChina
-
AB Biotics, SACompleted